ArticleCase reports in oncological medicine2020

Response to Ipilimumab/Nivolumab Rechallenge and BRAF Inhibitor/MEK Inhibitor Rechallenge in a Patient with Advanced Metastatic Melanoma Previously Treated with BRAF Targeted Therapy and Immunotherapy.

Caitlyn N Myrdal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.